Introduction
============

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune, inflammatory arthropathy of unknown etiology, characterized by progressive destruction of the affected joints, deformity, disability, and premature death \[[@B1]\]. Genetic and environmental factors have been implicated in the pathogenesis of RA \[[@B2]\]. The inflammatory response in the synovial membrane includes hyperplasia, increased vascularity, and infiltration of inflammatory cells \[[@B3]\]. Various inflammatory cascades ultimately lead to activation of macrophages and fibroblast-like synoviocytes to overproduce proinflammatory cytokines such as IL-1, IL-6, and TNFα \[[@B4],[@B5]\]. Other cytokines, as well as matrix metalloproteinases, are produced that are responsible for cartilage degradation and bone erosion.

IL-1 is considered a pivotal cytokine in chronic destructive arthritis; it is a strong activator of chondrocytes, induces cartilage breakdown through upregulation of metalloproteinases, and causes profound suppression of cartilage matrix synthesis. IL-1 is also able to increase receptor activator of NF-κB ligand expression and thus drive osteoclast formation and activation \[[@B6],[@B7]\], leading to bony erosions. Several murine models have shown the arthritogenic and erosive potency of IL-1. In collagen-induced arthritis, a frequently used animal model for RA, TNF was an important contributor to inflammation at the onset of disease, but IL-1 receptor (IL-1R) blockage was highly efficacious in reducing inflammation, both in acute and advanced stages \[[@B8]\]. In antigen-induced arthritis, cartilage damage, erosion progression, and propagation of inflammation are dependent on IL-1 \[[@B9],[@B10]\]. In a recent study of immune complex arthritis, IL-1-deficient mice were strongly protected \[[@B11]\]. In a novel transgenic mouse model of adjuvant arthritis, a pure T-cell model, mice deficient in the IL-1R antagonist displayed uncontrolled IL-1 activity and developed spontaneous T-cell-dependent autoimmune arthritis \[[@B12]\]. Overall, the preclinical data strongly support a role for IL-1 in the pathogenesis of synovial inflammation.

In RA patients, however, IL-1 antagonists display relatively modest effects, although they are very effective in the treatment of systemic-onset juvenile idiopathic arthritis, of adult-onset Still\'s disease, and of several autoinflammatory disorders \[[@B13]\]. The question remains whether these inhibitors were given at doses and intervals that would be able to achieve robust coverage of the IL-1 pathway. We therefore investigated whether use of more continuous blockade of IL-1 could translate into increased efficacy in the treatment of RA.

AMG 108 (Amgen Inc., Thousand Oaks, CA, USA) is a fully human IgG~2~monoclonal antibody that binds IL-1R type 1 and nonselectively inhibits the activity of both forms of IL-1 (IL-1α and IL-1β). The objective of the present study was to compare the efficacy and safety of three dose levels of AMG 108 with placebo in patients with active RA who were receiving stable methotrexate (MTX) (15 to 25 mg/week).

Materials and methods
=====================

Patients
--------

Patients were enrolled at 132 study sites in North America (43% of patients; United States, Canada, Mexico), Eastern Europe (43% of patients; Poland, Czech Republic, Hungary, Slovakia, Estonia, Latvia), Western Europe (12% of patients; Netherlands, Spain, Italy, United Kingdom, France, Belgium, Ireland, Sweden), and Australia (2% of patients).

Eligible patients were ≥18 and ≤70 years old and had RA that met the American College of Rheumatology (ACR) classification criteria \[[@B14]\], with active RA for a duration ≥6 months. Active RA was defined as ≥6 swollen joints and ≥6 tender or painful joints and at least one of the following: erythrocyte sedimentation rate (ESR) ≥28 mm/hour, C-reactive protein (CRP) \>2.0 mg/dl, or duration of morning stiffness ≥45 minutes at time of screening. Patients must have received MTX for at least 12 consecutive weeks, with a stable dose of oral or subcutaneous MTX at 15 to 25 mg/week for ≥4 weeks at time of screening. Exceptions were granted for a lower dose if it was the highest tolerated dose (toxicity documentation was required). Patients were allowed to be taking stable doses of nonsteroidal anti-inflammatory drugs or oral corticosteroids (≤10 mg prednisone or equivalent) if doses were stable ≥4 weeks before screening.

Patients were excluded from the study if they had received any previous AMG 108 or other commercial or experimental biologic therapies for RA or other inflammatory disease, or had uncontrolled or clinically significant systemic disease other than RA (for example, diabetes mellitus, cardiovascular disease, or hypertension). Patients could not have class IV RA as defined by ACR revised criteria for global functional status in RA \[[@B15]\], Felty\'s syndrome, a prosthetic joint infection within 5 years or native joint infection within 1 year of screening, or a major chronic inflammatory disease or connective tissue disease other than RA (with the exception of secondary Sjögren\'s syndrome). Patients could not have: uncontrolled or clinically significant asthma; known sensitivity to mammalian cell-derived drug products; malignancy within 5 years of screening (except for squamous or basal cell carcinoma or successfully treated in situ cervical cancer); serious infection (defined as requiring hospitalization) or recurrent, acute, or chronic infections within 8 weeks of screening; history of *Mycobacterium tuberculosis*or exposure; or known positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus.

Patients were ineligible if they had any of the following clinically significant laboratory values at screening: white blood cell count \<3.0 × 10^9^/l, absolute neutrophil count \<2.5 × 10^9^/l, platelet count \<125 × 10^9^/l, aspartate aminotransferase or alanine aminotransferase \>1.5 × upper limit of normal, serum creatinine \>1.5 × upper limit of normal, or any other laboratory abnormality that, in the opinion of the investigator, would prevent the patient from completing the study or would interfere with the interpretation of the study results. Patients could not have received intra-articular or systemic corticosteroid injections or any investigational therapy within 4 weeks of screening, any disease-modifying antirheumatic drug other than MTX within 6 weeks of screening, cyclophosphamide within 6 months of screening, or any live vaccine within 3 months of the first dose of investigational product. Patients were ineligible if, in the investigator\'s opinion, they had any physical or psychiatric disorder that could interfere with their ability to give informed consent or participate in the study. Patients with active substance abuse (within 6 months of screening) or any condition that might require narcotic analgesics were excluded. Pregnant or nursing women were not eligible, and all sexually active patients were required to use adequate contraception.

Study design
------------

The investigation was a double-blind, placebo-controlled, parallel-dosing study in patients with active RA who were receiving stable doses of MTX (15 to 25 mg/week), were biologic-naïve, and had discontinued disease-modifying antirheumatic drugs other than MTX prior to study entry. Patients were randomized equally to receive placebo or 50, 125, or 250 mg AMG 108 subcutaneously every 4 weeks for 6 months.

The study was conducted according to the Declaration of Helsinki and the International Conference on Harmonisation Tripartite Guideline on Good Clinical Practice \[[@B16]\]. Approvals from appropriate research ethics committees were obtained from each participating study center (Additional file [1](#S1){ref-type="supplementary-material"}). All patients provided written informed consent before participating. An external Data Monitoring Committee monitored patient safety throughout the duration of the study.

Endpoints
---------

The primary efficacy endpoint was the ACR20 response \[[@B17]\] at week 24. Secondary efficacy endpoints included ACR50 and ACR70 responses and the individual components of the ACR; the Disease Activity Score using the 28-joint count (DAS28) (using CRP primarily; ESR was used only if CRP was missing) \[[@B18]\]; and patient-reported outcomes, including the Disability Index of the Health Assessment Questionnaire \[[@B19]\], and the physical and mental composite scores of the Short Form-36 \[[@B20]\] at week 24. All of these endpoints over time in the study were analyzed as exploratory endpoints.

Safety endpoints included treatment-emergent adverse events (AEs), infectious AEs, serious AEs, serious infections, injection site reactions, laboratory abnormalities, and anti-AMG 108 antibodies.

The pharmacokinetic profile of AMG 108 in combination with MTX was also assessed (in 520 patients with sparse sampling, and in 37 patients with intensive sampling). A validated ELISA was used to quantify AMG 108 in the serum; IL-1R was used as the capture receptor, and biotinylated IL-1R was used for detection.

Binding antibodies to AMG 108 (anti-drug antibodies) were evaluated using a validated acid dissociation electrochemiluminescence-based bridging immunoassay. Serum samples were collected predose and at weeks 12, 24, and 34. A cell-based bioassay was used to detect neutralizing antibodies in samples that were positive in the immunoassay.

Sample size
-----------

The primary endpoint was the ACR20 response at week 24. The sample size of 196 patients per treatment arm was calculated to provide at least 80% power at a statistical significance level of 5% (two-sided) to test whether monthly subcutaneous dosing of AMG 108 in combination with MTX demonstrated an ACR20 response at week 24 that was \>20% above that with MTX therapy alone in RA subjects. The sample size was inflated to allow for a 10% dropout rate over the course of the study.

Statistical analysis
--------------------

Patients were analyzed according to the randomized treatment arm regardless of actual treatment received during the study. All efficacy endpoints were analyzed using the intent-to-treat analysis set, which included all randomized patients regardless of whether they received investigational product. The safety dataset included all patients who received ≥1 dose of investigational product.

The primary efficacy endpoint compared the ACR20 response rate at week 24 in the 250 mg AMG 108 group with that of the placebo group. All secondary endpoints were tested sequentially in a prespecified order to control the overall family-wise type 1 error rate at 5% (two-sided). The comparisons of proportions (for dichotomous variables) among treatment arms were carried out using Fisher\'s exact test. The comparisons of distribution-location parameters (for continuous and ordinal variables) among treatment arms were performed using the Wilcoxon rank-sum text. For dichotomous variables, missing values were imputed using a nonresponder imputation method; for continuous variables, the primary analysis is based on observed cases.

Results
=======

Patient disposition and disease characteristics
-----------------------------------------------

The patient disposition is presented in Figure [1](#F1){ref-type="fig"}. Randomization was well balanced across groups: 204 patients were randomized to 50 mg AMG 108, 203 patients to 125 mg AMG 108, 203 patients to 250 mg AMG 108, and 203 patients to placebo. Of 813 patients enrolled in the study, 805 (99%) received ≥1 dose of investigational product. Study completion at week 24 was similar across treatment groups: 88 to 90% in the AMG 108 groups vs. 93% in the placebo group.

![**Patient disposition**. CONSORT diagram.](ar3163-1){#F1}

Demographics and baseline disease characteristics are presented in Table [1](#T1){ref-type="table"}. Most patients were women (≥76% in each group), and most were white (≥83% in each group). The mean age was 51.8 years in the AMG 108 groups and was 52.1 years in the placebo group.

###### 

Baseline demographics and disease characteristics

                                                      AMG 108                                
  -------------------------------------- ------------ ------------ ------------ ------------ ------------
  Mean age (years)                       52.1         51.4         51.7         52.2         51.8
  Age group, *n*(%)                                                                          
   \< 65 years                           185 (91.1)   171 (83.8)   176 (86.7)   184 (90.6)   531 (87.0)
   ≥65 years                             18 (8.9)     33 (16.2)    27 (13.3)    19 (9.4)     79 (13.0)
  Female, *n*(%)                         158 (77.8)   155 (76.0)   163 (80.3)   160 (78.8)   478 (78.4)
  Ethnicity, *n*(%)                                                                          
   White                                 168 (82.8)   169 (82.8)   177 (87.2)   179 (88.2)   525 (86.1)
   Hispanic                              27 (13.3)    24 (11.8)    18 (8.9)     17 (8.4)     59 (9.7)
   Other^a^                              8 (3.9)      11 (5.4)     8 (3.9)      7 (3.4)      26 (4.3)
  Mean weight (kg)                       76.4         77.2         74.2         75.0         75.4
  Mean height (cm)                       164.0        164.6        164.0        164.8        164.5
  Mean body mass index (kg/m^2^)         28.4         28.4         27.5         27.5         27.8
  Mean duration of RA (years)            7.6          7.3          7.5          8.0          7.6
  Subcomponent of ACR (mean)                                                                 
   Tender joint count                    26.3         26.5         24.8         26.9         26.1
   Swollen joint count                   16.8         16.8         15.8         15.7         16.1
   Patient global assessment             5.9          6.2          6.1          6.1          6.2
   Physician global assessment           6.2          6.3          6.3          6.5          6.4
   Patient pain assessment               51.2         53.9         53.5         57.0         54.8
  HAQ Disability Index                   1.4          1.5          1.5          1.5          1.5
  C-reactive protein (mg/dl)             1.2          1.8          1.5          1.4          1.6
  ESR (mm/hour)                          33.4         40.1         35.6         35.5         37.1
  Mean DAS28 CRP                         4.7          4.9          4.7          4.8          4.8
  Mean DAS28 ESR                         5.3          5.4          5.3          5.4          5.3
  Mean tender joint count (28 joints)    14.0         14.5         13.5         14.0         14.0
  Mean swollen joint count (28 joints)   11.3         10.6         10.8         11.2         11.0

ACR, American College of Rheumatology; DAS28, Disease Activity Score (28-joint count); ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis. ^a^Black, Asian, American Indian or Alaska native, native Hawaiian or other Pacific Islander.

Efficacy
--------

In the primary efficacy analysis at week 24 (using the nonresponder imputation method), the ACR20 response rate was statistically significantly higher in the 250 mg AMG 108 group (40.4%) compared with the placebo group (29.1%; *P*= 0.022). Small improvements in the ACR20 response at week 24 were also seen in the 125 mg AMG 108 group (36.0%; Table [2](#T2){ref-type="table"}). The ACR20, ACR50, and ACR70 responses are presented in Table [2](#T2){ref-type="table"}. Only the 250 mg AMG 108 group showed a significant improvement in ACR50 scores, and no groups were different from placebo with respect to ACR 70.

###### 

ACR responses, DAS28 C-reactive protein, and EULAR28 responses at week 24

                                                          AMG 108                                           
  ----------------------------------------- ------------- ------------------------ ------------------------ -------------------------
  ACR response, *n*(%)^a^                                                                                   
   ACR20                                    59 (29.1)     63 (30.9) (*P*= 0.746)   73 (36.0) (*P*= 0.168)   82 (40.4) (*P*= 0.022)
   ACR50                                    17 (8.4)      24 (11.8) (*P*= 0.323)   28 (13.8) (*P*= 0.113)   41 (20.2) (*P*\< 0.001)
   ACR70                                    8 (3.9)       4 (2.0) (*P*= 0.259)     5 (2.5) (*P*= 0.575)     12 (5.9) (*P*= 0.492)
  DAS28 CRP, mean change from baseline^b^   -0.60         -0.69 (*P*= 0.213)       -0.92 (*P*\< 0.001)      -1.18 (*P*\< 0.001)
  EULAR28 response, *n*(%)^c^                                                                               
   Good                                     16 (8%)       20 (10%)                 28 (13.9%)               39 (19.5%)
   Moderate                                 61 (30.7%)    59 (29.3%)               76 (37.8%)               76 (38%)
   No response                              122 (61.3%)   122 (60.7%)              97 (48.3%)               85 (42.5%)

ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, Disease Activity Score (28-joint count); EULAR28, European League Against Rheumatism (28-joint count). ^a^Nonresponder imputation: missing ACR responses were imputed as nonresponder. *P*values are nominal without multiplicity adjustment, using Fisher\'s exact test. ^b^Observed cases. *P*values are comparisons with placebo, using two-sided Wilcoxon rank-sum test. ^c^EULAR28 response is classified as good, moderate, and no response based on the DAS28 ESR at week 24 and the DAS28 ESR improvement from baseline at week 24 \[[@B31]\].

Additionally, numerical dose-dependent responses were observed at week 24 in several individual components of the ACR, including tender joint count, pain (visual analog scale), ESR, and CRP; all components of the ACR are presented in Table [3](#T3){ref-type="table"}. Responses were weak or absent in swollen joint count and physician and patient global assessments. Median ESR values are shown over time in Figure [2](#F2){ref-type="fig"}.

###### 

Improvements in American College of Rheumatology and DAS28 components at week 24

                                                    AMG 108                        
  --------------------------------- --------------- -------------- --------------- ---------------
  Tender joint count (68 joints)                                                   
   Mean (SD) % change               -20.0 (127.5)   -29.5 (60.4)   -35.7 (43.6)    -40.2 (44.3)
   Median % change                  -31.3           -38.4          -40.0           -46.7
  Swollen joint count (66 joints)                                                  
   Mean (SD) % change               -32.2 (50.0)    -33.7 (46.5)   -33.8 (114.8)   -39.1 (53.3)
   Median % change                  -33.1           -40.8          -46.3           -47.1
  Patient global assessment                                                        
   Mean (SD) % change               -11.6 (49.8)    -16.7 (43.8)   -21.6 (48.2)    -17.8 (64.5)
   Median % change                  -20.0           -16.7          -28.6           -20.0
  Physician global assessment                                                      
   Mean (SD) % change               -30.1 (33.7)    -36.0 (30.4)   -36.2 (33.2)    -43.0 (30.8)
   Median % change                  -33.3           -37.5          -40.0           -50.0
  Pain (visual analog scale)                                                       
   Mean (SD) % change               2.2 (142.6)     -11.4 (76.3)   -20.6 (60.6)    -30.9 (46.9)
   Median % change                  -12.8           -20.0          -28.9           -34.7
  HAQ Disability Index                                                             
   Mean (SD) % change               -11.1 (53.0)    -12.2 (40.6)   -20.5 (48.2)    -25.2 (44.6)
   Median % change                  -11.4           -13.3          -20.0           -25.0
  Erythrocyte sedimentation rate                                                   
   Mean (SD) % change               12.7 (77.7)     5 (124.3)      -18.3 (68.7)    -30.4 (73.7)
   Median % change                  -6.3            -13.2          -36.8           -46.7
  C-reactive protein                                                               
   Mean (SD) % change               123.2 (695.3)   32.2 (164.0)   -1.9 (181.5)    -25.5 (168.5)
   Median % change                  5.1             -12.4          -41.2           -59.4
  Tender joint count (28 joints)                                                   
   Mean (SD) % change               -13.2 (143.7)   -21.0 (73.2)   -31.6 (58.7)    -36.5 (65.7)
   Median % change                  -33.3           -33.3          -40.0           -44.4
  Swollen joint count (28 joints)                                                  
   Mean (SD) % change               -28.2 (52.7)    -30.0 (48.1)   -28.7 (118.3)   -38.0 (52.2)
   Median % change                  -33.3           -33.3          -44.4           -44.4

DAS28, Disease Activity Score (28-joint count); HAQ, health assessment questionnaire; SD, standard deviation.
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Results of the DAS28 CRP at week 24 are presented in Table [2](#T2){ref-type="table"}. The 125 mg and 250 mg AMG 108 groups had significantly greater mean improvements from baseline compared with placebo at week 24 (-0.92 and -1.18, respectively, vs. -0.60; *P*\< 0.001). Of note, most patients had moderate disease activity at study entry, as shown by their baseline DAS28 CRP scores (Table [1](#T1){ref-type="table"}). The European League Against Rheumatism 28-joint count responses (EULAR28) are also presented in Table [2](#T2){ref-type="table"}.

Clinically meaningful improvements were observed in some patient-reported outcome measures. Mean improvements from baseline at week 24 in the Health Assessment Questionnaire Disability Index were greater in the 250 mg and 125 mg AMG 108 groups (-0.40 and -0.34, respectively; *P*\< 0.001, each group compared with placebo) than in the 50 mg group (-0.24) or the placebo group (-0.19). Mean improvements from baseline at week 24 in the physical composite score of the Short Form-36 were numerically greater in all AMG 108 groups (range 4.6 to 7.2) than in the placebo group (3.3), and were significantly greater in the 250 mg group (7.2) compared with placebo (*P*\< 0.001). Improvements in the mental composite score, however, were similar among the AMG 108 and placebo groups (data not shown).

Pharmacokinetics
----------------

Following single-dose and multiple-dose administration, AMG 108 is slowly absorbed - with the median time at which the maximum concentration occurs ranging from 3.8 to 3.9 days (50 mg group), from 3.9 to 4.0 days (125 mg group), and from 5.9 to 7.0 days (250 mg group). Trough pharmacokinetic levels in the 250 mg dose group were approximately 10-fold above the predicted 90% inhibitory concentration for IL-1 (Table [4](#T4){ref-type="table"}). Importantly, trough pharmacokinetic levels were maintained in the 125 mg and 250 mg groups, suggesting prolonged coverage of the IL-1 pathway.

###### 

Summary of AMG 108 trough concentration (nM) at 20 and 24 weeks

           50 mg AMG 108   125 mg AMG 108   250 mg AMG 108                         
  -------- --------------- ---------------- ---------------- ---------- ---------- ------------
  Mean     0               0                16.5             19.8       155        160
  Median   0               0                6.25             4.65       139        141
  Range    0 to 6.43       0 to 0.32        0 to 104         0 to 268   0 to 417   0 to 1,000

Below quantifiable levels reported as 0. 90% inhibitory concentration = 13.5 nM, 50% inhibitory concentration = 1.5 nM.

Safety
------

AMG 108 was well tolerated at all doses administered during the study. No increase in incidence of treatment-emergent AEs was observed with increasing AMG 108 dose (Table [5](#T5){ref-type="table"}). No deaths were reported, and the incidence of AEs, infectious AEs, serious AEs and infections, and withdrawals from study due to AEs were no higher in AMG 108 groups than in the placebo group (Table [5](#T5){ref-type="table"}).

###### 

Summary of adverse events through 24 weeks

                                              AMG 108                                
  ------------------------------ ------------ ------------ ------------ ------------ ------------
  Any AE                         133 (66.2)   134 (66.3)   143 (71.1)   135 (67.2)   412 (68.2)
  Most common AE                                                                     
   Headache                      16 (8.0)     11 (5.4)     15 (7.5)     15 (7.5)     41 (6.8)
   Diarrhea                      13 (6.5)     10 (5.0)     11 (5.5)     15 (7.5)     36 (6.0)
   Nasopharyngitis               18 (9.0)     11 (5.4)     13 (6.5)     12 (6.0)     36 (6.0)
   URI                           15 (7.5)     10 (5.0)     13 (6.5)     13 (6.5)     36 (6.0)
  Treatment-related AE           48 (23.9)    43 (21.3)    50 (24.9)    45 (22.4)    138 (22.8)
  AE leading to:                                                                     
   Study discontinuation         1 (0.5)      3 (1.5)      3 (1.5)      3 (1.5)      9 (1.5)
   Withdrawal of study drug      2 (1.0)      4 (2.0)      4 (2.0)      3 (1.5)      11 (1.8)
   Hospitalization               9 (4.5)      5 (2.5)      5 (2.5)      6 (3.0)      16 (2.6)
  Any infection                  72 (35.8)    64 (31.7)    68 (33.8)    62 (30.8)    194 (32.1)
  Infection leading to:                                                              
   Study discontinuation         1 (0.5)      0            0            1 (0.5)      1 (0.2)
   Withdrawal of study drug      0            1 (0.5)      0            1 (0.5)      2 (0.3)
   Hospitalization               3 (1.5)      1 (0.5)      1 (0.5)      2 (1.0)      4 (0.7)
  Injection site reaction        5 (2.5)      8 (4.0)      10 (5.0)     9 (4.5)      27 (4.5)
  Any serious AE                 11 (5.5)     6 (3.0)      6 (3.0)      9 (4.5)      21 (3.5)
  Treatment-related serious AE   2 (1.0)      2 (1.0)      1 (0.5)      1 (0.5)      4 (0.7)
  Serious infection              3 (1.5)      2 (1.0)      1 (0.5)      2 (1.0)      5 (0.8)
  Death                          0            0            0            0            0

Data presented as *n*(%). AE, adverse event; URI, upper respiratory infection. ^a^All randomized patients who received at least one dose of AMG 108.

Injection-site reactions occurred more frequently in AMG 108 groups than in the placebo group (Table [5](#T5){ref-type="table"}), but most reactions were mild or moderate in severity, with the majority of cases lasting \<5 days. Of the 604 patients who received ≥1 dose of AMG 108, 83 patients (13.7%) were positive for binding antibodies to AMG 108 at some time during the study; 22 patients (4%) were positive for neutralizing antibodies (data not shown).

No clinically significant changes in laboratory abnormalities were observed, with the exception of expected decreases in the absolute neutrophil count and platelet counts that were dose related; these decreases recovered to baseline values by the end-of-study evaluation (week 34; 10 weeks following the last dose of AMG 108). The median decreases in neutrophil counts over time are shown by visit and by treatment group in Figure [3](#F3){ref-type="fig"}.
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Discussion
==========

In the present study of AMG 108 - a long-acting IL-1R inhibitor - improvements in the signs and symptoms of RA as measured by the ACR20 were greater in the 250 mg AMG 108 group (40.4%) at week 24, compared with the placebo group (29.1%; *P*= 0.022). Improvements in the ACR50 were also statistically significant for the 250 mg AMG 108 group compared with placebo; however, the numbers of patients with ACR50 responses were low (20.2% vs. 8.4%, 250 mg AMG 108 vs. placebo, respectively; *P*\< 0.001). The ACR70 response was not significantly different between the two groups. Of note, mean responses on the Health Assessment Questionnaire Disability Index observed in all groups treated with AMG 108 were above the minimum clinically important difference (0.22) published for this outcome measure \[[@B21]\]. It is interesting that the components of the ACR responses showing dose-dependent effects in this study were those that are consistent with the known functions of IL-1 in pain \[[@B22]\] and in the acute phase response \[[@B23]\]: AMG 108 decreased pain, tender joints, ESR, and CRP. The other components of the ACR scoring system were not affected. AMG 108 was well tolerated in this patient population, with a safety profile similar to that of placebo. No dose-related increases were observed in the incidence of AEs, and no unanticipated events were reported.

Of interest, the effectiveness of IL-1R blockade with a long-acting receptor blocker, AMG 108, appears to be moderate and similar to those described with other IL-1 blockers (such as anakinra, pralnacasan, and IL-1 TRAP) \[[@B24]-[@B26]\], despite a constant concentration of drug estimated to be 10-fold higher than the predicted 90% inhibitory concentration for IL-1. The limited efficacy of IL-1 blockers in RA therefore appears not to be explained solely by pharmacokinetic or pathway coverage, since the efficacy provided by AMG 108 was similar to that in other IL-1 inhibitor studies \[[@B27]\] despite constant inhibition of the IL-1 pathway for a 6-month period with AMG 108.

The results of treatment with AMG 108 instead appear to point to a limited role of IL-1 in human RA synovial inflammation - a notion supported by the profound effect seen with other IL-1 inhibitors in conditions other than RA, such as systemic-onset juvenile idiopathic arthritis, gout, neonatal-onset multisystem inflammatory disease, cryopyrin-associated periodic syndromes, and other autoinflammatory disorders \[[@B28],[@B29]\]. Although it is not known how many IL-1Rs have to be blocked to prevent IL-1 binding and signaling in a substantial way, AMG 108 achieved steady concentrations in the 250 mg/month dosing arm that should have been 10-fold higher than those needed to inhibit 90% of IL-1 signaling. In addition, dose-dependent changes were seen in those parameters known to be affected by IL-1, such as pain and acute phase reactants. This discrepancy of the IL-1 effect between the animal models and RA patients may therefore be due to differences in timing of treatment, with animals treated at very early stages of disease and RA patients at later stages of chronic synovial inflammation, or may instead be due to differences between the cytokine interactions in rodents versus humans \[[@B30]\].

A limitation of the present study is the absence of radiographic evaluation. The primary analysis was focused on clinical signs and symptoms rather than on joint damage measured radiographically; we therefore do not know whether a more robust benefit than shown in the clinical findings would have been achieved if radiographs had been evaluated. Our results may possibly reflect a partial uncoupling of clinical and radiographic findings.

Conclusions
===========

The present large, double-blind, randomized trial with a long-acting IL-1R blocker, AMG 108, is consistent with the experience of other IL-1 blockers, represents a definitive experiment showing that IL-1 inhibition provides only moderate symptomatic amelioration of arthritis activity in the majority of RA patients, and provides an answer to a question that has been discussed for many years in the rheumatologic community - whether use of more continuous blockade of IL-1 could translate into increased efficacy in the treatment of RA.
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